Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

REGENXBIO

A second baby reportedly died in a study of Novartis' gene therapy, Zolgensma — sending shares of biotech Regenxbio into free fall Monday.

A Second Baby Died In A Gene Therapy Study — Slugging This Biotech Stock

An early look at the phase 3 STR1VE trial data reinforces data from phase 1 START trial for Zolgensma.

Ionis's Spinraza Still Bests Novartis's Zolgensma

bluebird bio

Bristol-Myers

Celgene

CRISPR Therapeutics

Editas Medicine

Guardant Health Inc

Genomic Health

Gilead Sciences

Illumina

Myriad Genetics

Invitae

Spark Therapeutics

Pacific Biosciences of California

Roche Holding AG

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

General Mills

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Sometimes you have to act while the iron's hot, and that's the case with these three big-name dividend payers right now.

Top Dividend Stocks to Buy Right Now

Novartis announced that the FDA had accepted its BLA for brolucizumab to treat patients with wet age-related macular degeneration.

Novartis' BLA Acceptance Allows Entrance Into Large And Turbulent Wet AMD Market

AstraZeneca

GlaxoSmithKline

Johnson & Johnson

Merck

Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.

Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

Zogenix

Novartis completed its spin-off of eye care specialist Alcon and Zogenix had a drug application rejected.

Spinning off a less-than-thrilling eye care business isn't the only reason.

Here's Why Novartis Is Sliding Today

Novartis could have been at the forefront of NASH therapeutics development

Novartis And Tropifexor In NASH, And The Market Assessment

Amgen

These two are intertwined in a legal tango that could get messy.

Why Amgen's Giving Novartis a Headache

Novartis sues Amgen as the latter issues termination notice for migraine drug.

Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig

Novartis reportedly sued its partner Amgen on Thursday, accusing the biotech of trying to welsh on their agreement to sell migraine treatment Aimovig. Novartis stock fell more than 1%.

Novartis Lawsuit Accuses Amgen Of Trying To Welsh On Migraine Deal

ADMA Biologics

Advaxis

Here's a roundup of top developments in the biotech space over the last 24 hours.

The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

Novartis obtained FDA approval for Mayzent to treat patients with secondary progressive multiple sclerosis.

Novartis' FDA Approval Opens The Door For New Treatment Option

Novartis AG announced Monday that it is adding to its immunomodulatory medicine portfolio with with an acquisition. 

Novartis Announces $1.575B Acquisition Of IFM Tre

Novartis pledged Monday to spend $1.6 billion to buy a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Among its drugs, IFM Tre is working on nonalcoholic steatohepatitis.

Novartis Snags A $1.6 Billion Buy That Could Rival These Biotechs

Biogen

A thousand gene therapies in development could get a lot more attention if these two live up to expectations this year.

2 Blockbuster Gene Therapy Programs to Watch in 2019

Axsome Therapeutics

Biogen threw in the towel with once-promising Alzheimer's disease drug aducanumab. But these three late-stage pipeline candidates could potentially still emerge as winners.

3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop

Allergan

Conatus Pharma

Intercept Pharma

NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.

NASH Scorecard So Far This Year: A Look at the Hits & Misses

AbbVie

Bayer AG

Eli Lilly

AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.

Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals

Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS. 

Novartis (NVS) Receives FDA Approval for MS Drug Mayzent

Biogen stock tumbled Wednesday after Novartis gained approval for a rival multiple sclerosis treatment, dubbed Mayzent. Multiple sclerosis drugs comprise a huge portion of Biogen's sales.

The Hits Just Keep Coming For Biogen As Rival Novartis Gains MS Drug Approval

Culminating a month that saw mostly favorable FDA verdicts, Novartis AG announced regulatory approval for its multiple sclerosis drug.

FDA Approves Novartis Drug To Treat More Severe Form Of Multiple Sclerosis

Rumors and announcements have left Novartis investors feeling confused.

Sale Of Sandoz: Will They Or Won't They?

Abbott Labs

Stryker

Two medical-device makers and one big drugmaker are on a roll. But can their momentum continue?

3 Blue Chip Stocks That Just Hit 52-Week Highs: Are They Buys?

News for Novartis Stock (NVS)